Neonatal Screening Program at the University Hospital of the Ribeirao Preto School of Medicine, São Paulo University, Brazil

O Programa de Triagem Neonatal do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Brasil, instituído em 1994 diagnosticou, até 2005, 76 crianças com hipotireoidismo congênito, 10 com fenilcetonúria e 25 com hemoglobinopatias, o que representou uma incidência de 1:2.595, 1:19.409, 1:4.120, respectivamente. Foram diagnosticadas 2.747 crianças com traço falciforme (1:37,5 nascidos vivos). A cobertura média do programa foi de 94,5%. Houve uma considerável melhora nos parâmetros de avaliação da qualidade do programa no período, porém, sem atingir os índices ideais. Campanhas visando à maior divulgação da importância da triagem neonatal são necessárias para aumentar a cobertura e a instituição do 3º dia de vida do recém-nascido como sendo o Dia do Teste do Pezinho poderia contribuir para que idades mais precoces de tratamento fossem atingidas, melhorando o prognóstico das crianças acometidas.The Neonatal Screening Program at the University Hospital of the Ribeirao Preto School of Medicine, São Paulo University, Brazil, was introduced in 1994. As of December 2005, congenital hypothyroidism had been diagnosed in 76 infants, phenylketonuria in 10, and hemoglobinopathies in 25, representing incidence rates of 1:2,595, 1:19,409, and 1:4,120, respectively. A total of 2,747 newborns had the sickle cell trait, i.e., were heterozygous for the sickle mutation (1:37.5 live births). The program's mean coverage during this period was 94.5%. There was major improvement in the parameters for evaluating the program's quality, although they were still far from ideal. Public-awareness campaigns on the importance of neonatal screening are needed to increase the program's coverage. Setting postnatal day 3 as the standard Day for the Heel Stick Test would help ensure treatment at earlier ages, thus improving prognosis for affected infants

Detection of carriers of abnormal haemoglobins, and their familiarization with their condition, in the population of the regions of S. José do Rio Preto and Presidente Prudente, S. Paulo (Brazil)

A study of abnormal haemoglobins among the inhabitants of S. José do Rio Preto and Presidente Prudente was conducted, using blood samples collected from 7,657 subjects attending health clinics in 48 towns of those regions during 1983-1984. For purposes of analysis the subjects were grouped by region of origin and racial features, 6,941 being classified as "caucasoid" and 716 as "negroid", the latter category including negroes, dark mulattoes, and light mulattoes. Electrophoretic techniques were used to detect abnormal haemoglobins, to determine the presence of haemoglobin types S and C, and isolate the polypeptide chains of other abnormal haemoglobins. Tests for quantification of haemoglobin A2 and fetal haemoglobin were performed as needed. Alpha and beta thalassaemias were diagnosed in accordance with principles established by the World Health Organization. These procedures detected abnormal haemoglobin in 266 (3.47%) of the study subjects. These included 173 specific molecular variants (169 of them being type S or type C variants) and 93 thalassaemias (4 of them being alpha thalassaemia and 89 beta thalassaemia, both in heterozygous state). Overall, the prevalence of abnormal haemoglobins was found to be higher among negroids (7.68%) than among the caucasoids (3.02%), and this difference was statistically significant (x²1; 0.01 = 6.64 x²1; 0.05 = 3.84). While the overall prevalence of abnormal haemoglobins among the S. José do Rio Preto subjects did not differ from prevalence among Presidente Prudente subjects, the prevalence of the genotypes detected among the populations analysed of these two cities, and their respective regions, was different. For S. José do Rio Preto and region, the Hb AS was more prevalent among the abnormal haemoglobins (63%), next came heterozygous beta thalassaemia (17%). For Presidente Prudente the prevalences of Hb AS and heterozygous beta thalassaemia, among the abnormal haemoglobins, were 46% and 40%, respectively. The preventive action to be taken was established by means of meetings at which medical and biological explanations were given to the carriers of abnormal haemoglobins. Overall, the results showed that similar studies offer better knowledge of genetic, biochemical and haemotological causes of these hereditary anaemias, and also provide the opportunity of discovering the importance that these pathological states have in the public health of the Brazilian population.Foram analisadas 7.657 amostras de sangue provenientes de 48 cidades das regiões de São José do Rio Preto e de Presidente Prudente, com o objetivo de detectar e conscientizar os portadores de hemoglobinas anormais. As análises efetuadas mostraram que 3,47% tinham hemoglobinas anormais, sendo 2,26% portadores de variantes moleculares (Hbs, AS, AC, SS, SC, AJ, AB2) e 1,21% de talasse-mias (alfa e beta). Os resultados obtidos evidenciaram que estudos semelhantes, além de propiciar o melhor conhecimento das causas genéticas, bioquímicas e hematológicas dessas alterações hereditárias, oferecem também a oportunidade de estimar a importância que essas patologias representam para a saúde pública do nosso país. A ação preventiva foi estabelecida por meio de reuniões de esclarecimentos médicos e biológicos aos portadores de hemoglobinas anormais

Intrahepatic Cholestasis in Sickle Cell Disease: A Case Report

Intrahepatic cholestasis (SCIC) is an uncommon but potentially fatal complication of sickle cell disease (SCD), with a high death rate, observed mainly in patients with homozygous sickle cell anemia. Herein, we describe a case of severe SCIC treated successfully with aggressive manual exchange transfusion (ET). The patient was admitted with enlarged liver and signs of hepatic failure, such as hyperbilirubinemia and coagulopathy. There was no evidence of viral hepatitis or biliary obstruction. We performed several sessions of ET in order to reduce the percentage of HbS to levels inferior to 30%, which was successfully accomplished. The patient had a complete recovery of hepatic function. This case has shown that ET is an effective treatment of SCIC and should be introduced early on the onset of this severe complication

Sickle cell disease and pregnancy: analysis of 34 patients followed at the Regional Blood Center of Ribeirão Preto, Brazil

Objective: The objective of this study was to verify the evolution of pregnancies in sickle cell patients followed at one institution over a period of 12 years (January 2000 to June 2012). Methods: The study evaluated 34 pregnant women with sickle cell disease with a mean age of 23.9 ± 5.3 years. The incidence of obstetric complications, non-obstetric complications linked to sickle cell disease and complications in the newborn were analyzed. Results: A total of 26% of the cases reported previous miscarriages, 20% had preterm labor, 10% had pre-eclampsia, and 5% had gestational diabetes. Forty-one percent of the deliveries were cesarean sections and 29% of patients required blood transfusions. In respect to sickle cell disease, 62% of patients had vaso-occlusive crises, 29% had acute chest syndrome, 23% had urinary tract infection, 15% had impaired cardiac function and 6% developed pulmonary hypertension. Only one patient died in the postnatal period due to acute chest syndrome. The mean gestational age was 37.8 ± 2.63 weeks, and mean newborn weight was 2.809 ± 643.8 g. There were seven fetal losses, including three stillbirths and four miscarriages. The impact of transfusion therapy on the incidence of maternal–fetal complications during pregnancy was evaluated. Conclusions: Pregnancy in sickle cell patients is still associated with complications. Although no statistical difference was observed between transfused and non-transfused women, there were no deaths (fetal or maternal) in transfused patients whereas one maternal death and three stillbirths occurred in non-transfused women. A larger study of sickle cell pregnant women will be necessary to elucidate the actual role of transfusion during pregnancy in sickle cell disease

Detecção e conscientização de portadores de hemoglobinopatias nas regiões de São José do Rio Preto e Presidente Prudente, SP (Brasil)

Foram analisadas 7.657 amostras de sangue provenientes de 48 cidades das regiões de São José do Rio Preto e de Presidente Prudente, com o objetivo de detectar e conscientizar os portadores de hemoglobinas anormais. As análises efetuadas mostraram que 3,47% tinham hemoglobinas anormais, sendo 2,26% portadores de variantes moleculares (Hbs, AS, AC, SS, SC, AJ, AB2) e 1,21% de talasse-mias (alfa e beta). Os resultados obtidos evidenciaram que estudos semelhantes, além de propiciar o melhor conhecimento das causas genéticas, bioquímicas e hematológicas dessas alterações hereditárias, oferecem também a oportunidade de estimar a importância que essas patologias representam para a saúde pública do nosso país. A ação preventiva foi estabelecida por meio de reuniões de esclarecimentos médicos e biológicos aos portadores de hemoglobinas anormais.A study of abnormal haemoglobins among the inhabitants of S. José do Rio Preto and Presidente Prudente was conducted, using blood samples collected from 7,657 subjects attending health clinics in 48 towns of those regions during 1983-1984. For purposes of analysis the subjects were grouped by region of origin and racial features, 6,941 being classified as caucasoid and 716 as negroid, the latter category including negroes, dark mulattoes, and light mulattoes. Electrophoretic techniques were used to detect abnormal haemoglobins, to determine the presence of haemoglobin types S and C, and isolate the polypeptide chains of other abnormal haemoglobins. Tests for quantification of haemoglobin A2 and fetal haemoglobin were performed as needed. Alpha and beta thalassaemias were diagnosed in accordance with principles established by the World Health Organization. These procedures detected abnormal haemoglobin in 266 (3.47%) of the study subjects. These included 173 specific molecular variants (169 of them being type S or type C variants) and 93 thalassaemias (4 of them being alpha thalassaemia and 89 beta thalassaemia, both in heterozygous state). Overall, the prevalence of abnormal haemoglobins was found to be higher among negroids (7.68%) than among the caucasoids (3.02%), and this difference was statistically significant (x²1; 0.01 = 6.64 x²1; 0.05 = 3.84). While the overall prevalence of abnormal haemoglobins among the S. José do Rio Preto subjects did not differ from prevalence among Presidente Prudente subjects, the prevalence of the genotypes detected among the populations analysed of these two cities, and their respective regions, was different. For S. José do Rio Preto and region, the Hb AS was more prevalent among the abnormal haemoglobins (63%), next came heterozygous beta thalassaemia (17%). For Presidente Prudente the prevalences of Hb AS and heterozygous beta thalassaemia, among the abnormal haemoglobins, were 46% and 40%, respectively. The preventive action to be taken was established by means of meetings at which medical and biological explanations were given to the carriers of abnormal haemoglobins. Overall, the results showed that similar studies offer better knowledge of genetic, biochemical and haemotological causes of these hereditary anaemias, and also provide the opportunity of discovering the importance that these pathological states have in the public health of the Brazilian population

Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil

CONTEXT AND OBJECTIVES Sickle cell disease (SCD) is the most common genetic disorder among people of African descent, affecting approximately 3,500 newborns each year in Brazil. Hydroxyurea (HU) is the only effective drug to treating patients with SCD, thereby reducing morbidity and mortality. The objective was to analyze the effects of HU on SCD patients at our institution. DESIGN AND SETTING Retrospective study conducted at a sickle cell centre in Ribeirão Preto, São Paulo, Brazil. METHODS We analyzed clinical and laboratory data on 37 patients. The hematological parameters and clinical events that occurred during the year before and the first year of treatment with HU were analyzed. The mean dose of HU was 24.5 ± 5.5 mg/kg/day. RESULTS There were rises in three parameters: hemoglobin (8.3 g/dl to 9.0 g/dl, P = 0.0003), fetal hemoglobin (HbF) (2.6% to 19.8%, P < 0.0001) and mean cell volume MCV (89 to 105 fl, P = 0.001); and reductions in the numbers of leukocytes (10,050/µl to 5,700/µl, P < 0.0001), neutrophils (6,200/µl to 3,400/µl, P = 0.001), platelets (459,000/µl to 373,000/µl, P = 0.0002), painful crises (1.86 to 0.81, P = 0.0014), acute chest syndromes (0.35 to 0.08, P = 0.0045), infections (1.03 to 0.5, P = 0.047), hospitalizations (1.63 to 0.53, P = 0.0013) and transfusions (1.23 to 0.1, P = 0.0051). CONCLUSION The patients presented clinical and hematological improvements, with an increase in HbF and a reduction in the infection rate, which had not been addressed in most previous studies